These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32653473)

  • 21. Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer.
    Yoo SH; Kim TY; Kim M; Lee KH; Lee E; Lee HB; Moon HG; Han W; Noh DY; Han SW; Kim TY; Im SA
    Clin Breast Cancer; 2020 Apr; 20(2):98-107.e1. PubMed ID: 31522959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.
    Geffen DB; Abu-Ghanem S; Sion-Vardy N; Braunstein R; Tokar M; Ariad S; Delgado B; Bayme M; Koretz M
    Ann Oncol; 2011 Nov; 22(11):2381-2386. PubMed ID: 21363879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.
    Henry NL; Braun TM; Ali HY; Munir K; Silver SM; Gorski DH; Breslin TM; Griggs JJ
    Cancer; 2017 May; 123(6):948-956. PubMed ID: 27787892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
    Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mammaprint™: a comprehensive review.
    Brandão M; Pondé N; Piccart-Gebhart M
    Future Oncol; 2019 Jan; 15(2):207-224. PubMed ID: 30156427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 21-Gene Recurrence Score in Male Breast Cancer.
    Turashvili G; Gonzalez-Loperena M; Brogi E; Dickler M; Norton L; Morrow M; Wen HY
    Ann Surg Oncol; 2018 Jun; 25(6):1530-1535. PubMed ID: 29520654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
    Kittaneh M; Badve S; Caldera H; Coleman R; Goetz MP; Mahtani R; Mamounas E; Kalinsky K; Lower E; Pegram M; Press MF; Rugo HS; Schwartzberg L; Traina T; Vogel C
    Clin Breast Cancer; 2020 Jun; 20(3):183-193. PubMed ID: 32014370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer.
    Zeng Y; Gao W; Lin L; Chen X; Shen K
    J Geriatr Oncol; 2020 Jun; 11(5):843-849. PubMed ID: 31704037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.
    Enewold L; Geiger AM; Zujewski J; Harlan LC
    Breast Cancer Res Treat; 2015 May; 151(1):149-56. PubMed ID: 25859924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Chen J; Wu X; Christos PJ; Formenti S; Nagar H
    Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.
    Lynch JA; Berse B; Coomer N; Kautter J
    Genet Med; 2017 Oct; 19(10):1134-1143. PubMed ID: 28333918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients.
    Li Y; Kurian AW; Bondarenko I; Taylor JMG; Jagsi R; Ward KC; Hamilton AS; Katz SJ; Hofer TP
    Breast Cancer Res Treat; 2017 Feb; 161(3):587-595. PubMed ID: 28012085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.
    Mittmann N; Earle CC; Cheng SY; Julian JA; Rahman F; Seung SJ; Levine MN
    J Clin Oncol; 2018 Jan; 36(3):238-243. PubMed ID: 29193984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved Prognostication for the Updated AJCC Breast Cancer Pathological Prognostic Staging Varied in Higher-Stage Groups.
    Hu J; Fung MW; Tsang JY; Poon IK; Chan SK; Cheung SY; Hu H; Zhou D; Tse GM
    Clin Breast Cancer; 2020 Jun; 20(3):253-261.e7. PubMed ID: 32205037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer.
    Kizy S; Altman AM; Marmor S; Denbo JW; Jensen EH; Tuttle TM; Hui JYC
    J Geriatr Oncol; 2019 Mar; 10(2):322-329. PubMed ID: 30093354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
    Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
    Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
    Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
    [No Abstract]   [Full Text] [Related]  

  • 39. Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer.
    Yang DD; Buscariollo DL; Cronin AM; Weng S; Hughes ME; Bleicher RJ; Cohen AL; Javid SH; Edge SB; Moy B; Niland JC; Wolff AC; Hassett MJ; Punglia RS
    Radiat Oncol; 2020 Aug; 15(1):198. PubMed ID: 32799886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.
    Dzimitrowicz H; Mougalian S; Storms S; Hurd S; Chagpar AB; Killelea BK; Horowitz NR; Lannin DR; Harigopal M; Hofstatter E; DiGiovanna MP; Adelson KB; Silber A; Abu-Khalaf M; Chung G; Zaheer W; Abdelghany O; Hatzis C; Pusztai L; Sanft TB
    J Oncol Pract; 2017 Dec; 13(12):e1012-e1020. PubMed ID: 29048991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.